This study provides evidence that high-dose therapy and autologous stem cell transplantation performed in the outpatient setting can result in excellent outcomes for selected myeloma patients.
Myeloma escape from immunity: an “inside” job. Rapoport AP. Blood. 2015 Sep 17;126(12):1401-3. doi: 10.1182/blood-2015-07-659490. Antibody based immunotherapy for multiple myeloma: It’s about time. Sher T et al, Leuk Lymphoma. 2015 Sep 16:1-17. [Epub ahead of print]. Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies. Karp Leaf R et al. Curr Hematol Malig Rep. 2015 Sep 4. [Epub ahead of…
Early Surgical Occipito-Cervical Stabilization for Plasma Cell Neoplasms at the Cranio-Cervical Junction – Systematic Review and Proposal of a Treatment Algorithm. Ahmadi SA et al. Spine J. 2015 Sep 24. pii: S1529-9430(15)01442-4. doi: 10.1016/j.spinee.2015.09.032. [Epub ahead of print]. Pathologic sternal involvement is a potential risk factor for severe sagittal plane deformity in multiple myelomawith concomitant thoracic fractures. Butler JS et…
Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma. Lin TL et al. J Clin Apher. 2015 Sep 5. doi: 10.1002/jca.21421. [Epub ahead of print]. Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. Jagirdar N et al. Transfusion. 2015 Sep 2.…
The IMWG report on the newly developed revised version of the International Staging System (R-ISS) which incorporates chromosomal abnormalities to develop a more powerful staging system for stratifying myeloma patients.
Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.
Yadav P et al. Eur J Haematol. 2015 Aug 6. doi: 10.1111/ejh.12644. [Epub ahead of print].
Re-invigorating rather than re-inventing the wheel: augmenting the impact of salvage autologous stem cell transplantation for multiple myeloma in the era of novel agents. Cook G. Bone Marrow Transplant. 2015 Aug 3. doi: 10.1038/bmt.2015.175. [Epub ahead of print]. IgG Lambda Myeloma Presenting as Plasmacytic Ascites: Case Report and Review of Literature. Mitra S et al. Indian J Hematol Blood Transfus. 2015 Dec;31(4):472-9. doi: 10.1007/s12288-014-0454-5.…
Rapid evolving into acute myeloid leukemia in a patient with multiple myeloma and concurrent myelodysplasia after VTD therapy. Gu ZH et al. Int J Clin Exp Med. 2015 Jun 15;8(6):10105-10108. Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma. Vincent L et al. Blood Cancer J. 2015 Aug 21;5:e341. doi: 10.1038/bcj.2015.48. Hematopoietic cell transplantation in patients with medication-related osteonecrosis of the jaws. Mawardi…
Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. Palumbo A et al. J Clin Oncol. 2015 Aug 17. pii: JCO.2014.60.2466. [Epub ahead of print]. Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myelomapatients aged 65 years or older: a retrospective single Institutional analysis. Minoia C et al. Bone Marrow Transplant. 2015 Aug…